Skip to main content

Market Overview

UPDATE: Jefferies Lowers PT on Zoetis Following SOTP Analysis


In a report published Tuesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Zoetis (NYSE: ZTS), but lowered the price target from $41.00 to $40.00.

In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation of undervalued assets we have prepared a highly proprietary sum of the parts analysis for our coverage universe to find the best opportunities. As a result we have upgraded Bayer and Merck & Co. to Buy from Hold and Eli Lilly to Hold from U/P, though it remains our least preferred stock. Novartis and Abbott are now our Top European and US picks respectively.”

Zoetis closed on Friday at $33.46.

Latest Ratings for ZTS

Mar 2021Raymond JamesUpgradesMarket PerformOutperform
Mar 2021B of A SecuritiesUpgradesNeutralBuy
Feb 2021Credit SuisseMaintainsOutperform

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings


Related Articles (ZTS)

View Comments and Join the Discussion!

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at